<DOC>
	<DOCNO>NCT01422824</DOCNO>
	<brief_summary>This prospective observational study evaluate safety efficacy Mircera ( methoxy polyethylene glycol-epoetin beta ) patient chronic renal anemia haemodialysis maintenance ESA treatment . Data collect patient receive monthly Mircera accord standard care local label 12 month treatment .</brief_summary>
	<brief_title>An Observational Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Maintenance Treatment Patients With Chronic Renal Anemia Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Stage IV chronic kidney disease , haemodialysis Chronic renal anemia , maintenance ESA treatment Hemoglobin concentration 10.0 12 g/dL Continuous maintenance epoetin therapy dose interval previous month Contraindications ESA treatment ( e.g . hypersensitivity , noncontrolled hypertension ) Hemoglobinopathies ( e.g . homozygous sicklecell disease , thalassemia type ) Anemia due hemolysis , pure red cell aplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>